| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/28/2005 | WO2005037304A1 Treatment and prevention of decubitus |
| 04/28/2005 | WO2005037293A1 Immunomodulating compositions and uses therefor |
| 04/28/2005 | WO2005037288A1 A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof |
| 04/28/2005 | WO2005037284A1 Sorbitol dehydrogenase inhibitor and hypertensive agent combinations |
| 04/28/2005 | WO2005037263A1 Breast cancer treatment regimen |
| 04/28/2005 | WO2005037260A2 Use of adrenergic alphaze antagonists for the treatment of vasomotor symptoms |
| 04/28/2005 | WO2005037259A2 Methods and compositions for the prevention or treatment of neoplasia comprising a cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| 04/28/2005 | WO2005037249A1 Oral microemulsion composition comprising biphenyldimethyldicarboxylate and silybin |
| 04/28/2005 | WO2005037245A2 A multiple route medication for the treatment of rhinitis and asthma |
| 04/28/2005 | WO2005037225A2 Methods for treating disorders of neuronal deficiency with bone marrow-derived cells |
| 04/28/2005 | WO2005037219A2 Disinfecting teat care compositions |
| 04/28/2005 | WO2005037203A2 Methods and reagents for the treatment of immunoinflammatory disorders |
| 04/28/2005 | WO2005037192A2 Ibuprofen narcotic composition and method for making same |
| 04/28/2005 | WO2005018622A8 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 04/28/2005 | WO2005007811A3 Injection of bone marrow-derived cells and medium for angiogenesis |
| 04/28/2005 | WO2004084905A3 Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions |
| 04/28/2005 | WO2004032963A9 Photokinetic delivery of biologically active substances using pulsed incoherent light |
| 04/28/2005 | WO2004005262A8 New neuropeptide y y5 receptor antagonists |
| 04/28/2005 | WO2003095971A3 Posh nucleic acids, polypeptides and related methods |
| 04/28/2005 | WO2003068929A3 Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors |
| 04/28/2005 | WO2003044170A3 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 04/28/2005 | US20050091703 Nonhuman model animal of th2-mediated hyperimmune response |
| 04/28/2005 | US20050090693 Clusianon derivatives; anticarcinogenic, antitumor and viricidal agents; mixture with mitogen-activated protein (MAP) kinase inhibitors |
| 04/28/2005 | US20050090562 1-benzoyl-8,8-dimethyl-2-hydroxy-3,5,7-tris(3-methyl-2-butenyl)bicyclo- [3.3.]non-2-ene-4,9-dione and a protein kinase inhibitor; antineoplastic agents; antiproliferative agents |
| 04/28/2005 | US20050090558 Suppressing immune response in a mammal comprising accelerating lymphocyte homing (ALH) to any of mesenteric or peripheral lymph tissues or Peyer's patches by administering an ALH-immunosuppressive compound |
| 04/28/2005 | US20050090556 Method for treatment of external secretion disorders |
| 04/28/2005 | US20050090553 Compositions and method for treatment of chronic inflammatory diseases |
| 04/28/2005 | US20050090547 Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| 04/28/2005 | US20050090538 Potentiating an NSAID and/or acetaminophen analgesic by administering concurrently a cyclooxygenase-2 inhibitor such as celecoxib, meloxicam, nimesulide and/or rofecoxib |
| 04/28/2005 | US20050090537 Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof |
| 04/28/2005 | US20050090536 Substituted pyrrol-3-ylisoxazoles, e.g., N-benzyl-4-[4-(o-chlorophenyl)-5-isoxazolyl)pyrrole-2-carboxamide; treating diseases that are alleviated by a protein kinase inhibitor, particularly cancer, inflammatory disorders, restenosis, and cardiovascular disease. |
| 04/28/2005 | US20050090522 E.g., 1-benzoyl-3-(R)-methyl-4-[(7-(4-fluorophenyl)-6-azaindol-3-yl)-oxoacetyl]piperazine; antiviral agents, especially for the treatment of HIV and AIDS, either used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. |
| 04/28/2005 | US20050090517 Pharmaceutical combinations of cox-2 inhibitors and opiates |
| 04/28/2005 | US20050090513 Compounds specific to adenosine a1 and a3 receptors and uses thereof |
| 04/28/2005 | US20050090511 Synergistic combination of theanine and cystine for administration with foods, feeds, and beverages bases, confectioneries or powders; viricides, bactericides |
| 04/28/2005 | US20050090507 Administered singly or in combination with a second antineoplastic agent; cyclin-dependent kinase inhibitors, antiproliferative agents; coupling and cyclization of a 1-aminopyridazinium salt with a 2-alkylthio-4-alkynyl pyrimidine compound |
| 04/28/2005 | US20050090503 5-HT receptor ligands and uses thereof |
| 04/28/2005 | US20050090502 Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents |
| 04/28/2005 | US20050090500 Oral administration of a crystalline form of erlotinib hydrochloride to treat cancer expressing epidermal growth factor receptor (EGFR), including non-small cell lung cancer, head and neck cancer, or ovarian cancer |
| 04/28/2005 | US20050090489 An alpha hydroxy acid or a retinoid as a bacterial fermentation product of a novel Streptomyces strain; topical antiwrinkle agents |
| 04/28/2005 | US20050090480 preventing malaria comprising administering drugs that inhibition of growth of the malarial parasite, plasmodium falciparum, along with phosphono derivatives and/or other drugs; parasiticides |
| 04/28/2005 | US20050090454 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease |
| 04/28/2005 | US20050090451 Treatment of cancer with glutamine |
| 04/28/2005 | US20050090441 inducing prolonged in vivo gene expression in mammal by contacting nonmuscular tissue with a nucleic acid, a histone, and an amphipathic compound; animal models: |
| 04/28/2005 | US20050089984 Having a specific amino acid sequence, especially fused to a heterologous polypeptide; induces apoptosis |
| 04/28/2005 | US20050089970 Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use |
| 04/28/2005 | US20050089945 Abeta 42 lowering agents |
| 04/28/2005 | US20050089938 For treatment of epilepsy, hypertension, angina pectoris, cerebral ischaemia, Parkinson's disease, insulin-dependent diabetes, and/or Lambert-Eaton myasthenic syndrome |
| 04/28/2005 | US20050089933 Compositions and methods for surrogate antibody modulation of an immune response and transport |
| 04/28/2005 | US20050089897 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 04/28/2005 | US20050089892 Biiodrugs for diagnosis, drug screening, clinical trial monitoring, treatment of physiological disorders; viral disease and infection prevention; expression vectors |
| 04/28/2005 | US20050089855 Expression vector comprising nucleotide sequences coding glycine transport protein for use in identifying modulator for treatment and prevention of nervous system and psychiatric disorders |
| 04/28/2005 | US20050089587 Procedure for the preparation of microbiological associations intended to strengthen the medicinal herb's therapeutic qualities |
| 04/28/2005 | US20050089584 Nut extract having different alkaloid profile; reduced level of carcinogens; supercritical CO2 extraction; maintaining nutraceutical effects; rapidly dissolving tablets |
| 04/28/2005 | US20050089578 Methods and devices for tissue repair |
| 04/28/2005 | US20050089575 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof |
| 04/28/2005 | US20050089574 Overcoating drug; sustained release; cardiovascular disorders; mixture of acrylic polymer and vinyl acetate polymer |
| 04/28/2005 | US20050089559 Flupirtine in combination with tolperisone or its analogs, such as eperisone or silperisone; pains which are accompanied by an increase in muscle tone such as neuralgia |
| 04/28/2005 | US20050089555 Administering phospholipid, bile acid and water; treating adipose tissue disorders such as cellulite, tumors e.g. lipomas |
| 04/28/2005 | US20050089546 Compositions and methods comprising complex carbohydrate and alpha-lactalbumin |
| 04/28/2005 | US20050089539 Antimicrobial compositions and methods |
| 04/28/2005 | US20050089535 Delivery of biologically active agents |
| 04/28/2005 | US20050089518 Prospective identification and characterization of breast cancer stem cells |
| 04/28/2005 | US20050089516 Artificial skin; mixture of protein and serine protease inhibitor |
| 04/28/2005 | US20050089511 Methods and compositions comprising DNA damaging agents and p53 |
| 04/28/2005 | US20050089485 Sulfacetamide formulations for treatment of rosacea |
| 04/28/2005 | US20050089479 Delivery of sedative-hypnotics through an inhalation route |
| 04/28/2005 | US20050089477 Medicaments |
| 04/28/2005 | US20050087198 Method for systemic drug delivery through the nail |
| 04/28/2005 | CA2542765A1 Method of inhibiting secretase activity |
| 04/28/2005 | CA2542694A1 Compounds for dual photodiagnosis and therapy |
| 04/28/2005 | CA2542691A1 Il-6 antagonist for use as mesothelioma therapeutic agent |
| 04/28/2005 | CA2542634A1 Disinfecting teat care compositions |
| 04/28/2005 | CA2542395A1 Treatment of arthritic conditions, chronic inflammation or pain |
| 04/28/2005 | CA2542332A1 Immunomodulating compositions and uses therefor |
| 04/28/2005 | CA2542155A1 Poxvirus vector encoding retrovirus (eg hiv) and cytokine |
| 04/28/2005 | CA2542074A1 Methods and reagents for the treatment of immunoinflammatory disorders |
| 04/28/2005 | CA2541264A1 Breast cancer treatment regimen |
| 04/27/2005 | EP1525883A1 Ciclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 04/27/2005 | EP1525323A2 Pgc-beta, a novel pgc-1 homologue and uses therefor |
| 04/27/2005 | EP1525308A2 Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
| 04/27/2005 | EP1525307A2 Modified adamts4 molecules and method of use thereof |
| 04/27/2005 | EP1525306A1 Three-dimensional structure of dipeptidyl peptidase iv |
| 04/27/2005 | EP1525209A2 1'-, 2'- and 3' -modified nucleoside derivatives for treating flaviviridae infections |
| 04/27/2005 | EP1525186A1 Inhibitors of hcv ns5b polymerase |
| 04/27/2005 | EP1525183A1 Inhibitors of hcv ns5b polymerase |
| 04/27/2005 | EP1525030A1 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 04/27/2005 | EP1525018A1 Medicament dispenser |
| 04/27/2005 | EP1524996A2 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 04/27/2005 | EP1524984A1 Myocardial perfusion imaging using a2a receptor agonists |
| 04/27/2005 | EP1524977A2 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 04/27/2005 | EP1524974A2 Transcription factor modulating compounds and methods of use thereof |
| 04/27/2005 | EP1524973A1 A pharmaceutical composition useful for treating chronic myeloid leukemia |
| 04/27/2005 | EP1524971A1 Improved transdermal delivery system |
| 04/27/2005 | EP1455799B1 Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists |
| 04/27/2005 | EP1424996B1 Method for the production of inhalation powders |
| 04/27/2005 | EP1423739A4 Source wavelength shifting apparatus and method for delivery of one or more selected emission wavelengths |
| 04/27/2005 | EP1289519A4 Methods of treating androgen deficiency in men using selective antiestrogens |
| 04/27/2005 | EP1286668B1 Pharmaceutical combinations comprising tegaserod und omeprazole and their use in treating gastrointestinal disorders |
| 04/27/2005 | EP1253932B1 Botulinum toxin pharmaceutical compositions |